3 ms·
This seems implausible. It’s extremely difficult to find cures in the first place, and in the event a company does, the US is willing to pay a ton for them (se
by lotsofpulp 6y ago
This seems implausible. It’s extremely difficult to find cures in the first place, and in the event a company does, the US is willing to pay a ton for them (see recent Hep C medications).
I would need more proof before being able to believe an executive team would throw away a sellable cure for an extremely low probability of finding a longer term rent seeking subscription plan.
- whatshisface 6y agoNot all diseases are bad enough to justify enormous pricetags for a cure.
- lotsofpulp 6y agoI am not aware of any diseases where the US government would not pay for a cure if there is a known cure for it because the price to “how bad is the disease” ratio is too high.
- lupire 6y agoWhat do you mean? The US government doesn't buy cures.
- hyperdimension 6y agoIt's called an orphan drug--when it's too expensive to make a profit on it, the FDA (IIRC) steps in and subsidizes it.
- lotsofpulp 6y agoI actually meant that Medicare/Medicaid/Tricare (aka US government) do not specifically reject treatment because of price. ACA also requires managed care organizations (aka health insurance companies) to cover pretty much all proven treatments. As an example, the new Hep C medications are $80k+ per dose or something if I recall correctly, and Medicaid pays for it.
- deleted 6y ago[deleted]
- ska 6y agoThis is certainly true, but it describes why companies don't start or continue the research. This has nothing to do with killing off a clinical stage drug because it was "too successful". The latter, as reported by GP, doesn't seem very plausible.
- Miner49er 6y agoI recently learned of some research that had a human trial that looked like it could potentially cure Multiple sclerosis (MS) and even potentially many (maybe all?) autoimmune diseases. However, it was too expensive, so no pharmaceutical companies picked it up. It was only when the researchers found a cheaper way of doing it that biopharmas were interested. Source is in this video, link starts at 5:35, watch until 8:15ish. https://youtu.be/J8vdDy7SN9k?t=335 https://youtu.be/J8vdDy7SN9k?t=335